More News

Clarifi Imaging System for Microvascular Assessment Receives CE Mark An Important Milestone for Modulim

The CE Mark certification allows Modulim to now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

The Ultimate End of Life Planning Checklist

With Pillar, you can get ahead of that by proactively planning. Take things one day at a time so you can be less stressed in the future and focus more on the real things that matter – the person you love.

RapidAI Acquires EndoVantage

RapidAI, the worldwide leader in advanced imaging for stroke, today (June 9, 2020) announced the acquisition of EndoVantage, developer of the Find, Track and Treat™ comprehensive cerebral aneurysm management platform. A major neurological condition, it is estimated that 1 in 50 people in the U.S. has an unruptured cerebral aneurysm, with one rupturing and resulting in a brain hemorrhage every 18 minutes. With this news, RapidAI continues to expand its scope, from ischemic stroke to hemorrhagic stroke and now aneurysm.

In 2019, RapidAI introduced Rapid ICH, the next step in AI-powered imaging technology for hemorrhages. Now with the acquisition of EndoVantage, the company will also add a concentration on aneurysm. Started at Mayo Clinic and Arizona State University, EndoVantage has developed a powerful award-winning computational platform that provides comprehensive cerebral aneurysm management, automating the entire workflow from initial assessment, growth monitoring, to treatment planning. It utilizes CTA and MRA scans to deliver results that help physicians find and track aneurysm progression, and leverages data from 3D rotational angiograms to deliver detailed 3D models of a patient’s vasculature and allow presurgical planning for the repair of the aneurysm.

“By adding the incredible technology developed by EndoVantage to the Rapid platform, we strengthen our position as the global leader in cerebrovascular imaging,” said Don Listwin, CEO of RapidAI. “We can offer hospitals a complete portfolio of products—encompassing ischemic stroke, hemorrhagic stroke, and aneurysm—providing an end-to-end solution that will drive better patient outcomes across the spectrum of cerebrovascular disorders.”

“We are very excited to join the Rapid platform of technology. EndoVantage covers the spectrum of cerebral aneurysm care from diagnosis through treatment, which helps physicians decide how best to treat their patients,” said Brian Chong MD, cofounder, EndoVantage. “Each patient’s aneurysm is unique, like the patient. Our technology augments a physician’s clinical acumen and experience helping them determine the best plan for each patient.”

The complete Rapid® platform currently includes:

  • Rapid ICH: automatically triages non-contrast CT scans to quickly identify brain hemorrhages with a sensitivity of 95% and specificity 94%*
  • Rapid ASPECTS**: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury
  • Rapid CTA: automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of large vessel occlusions (LVOs)**.
  • Rapid CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time
  • Rapid MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival
  • Rapid Mobile App: securely view Rapid results from multiple sites with customizable notifications on mobile devices

*When instances of hemorrhagic transformation type HI 1 are not included.
**Rapid ASPECTS and LVO detection and localization are not commercially available in the U.S.

Latest Posts

TRIMEDX Acquires Centurion Service Group a Full-Service Surplus Medical Equipment Management Company

TRIMEDX’s acquisition of Centurion Service Group will enhance TRIMEDX’s clinical asset management and informatics solutions.

Clarifi Imaging System for Microvascular Assessment Receives CE Mark An Important Milestone for Modulim

The CE Mark certification allows Modulim to now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Muvr Labs Is Acquired by Exactech

Orthopaedic surgeon Alexander Sah, MD, in Fremont, Calif. has seen the positive impact of Muvr technology on his practice. “Patients are attracted to the technology because they know our team is monitoring their progress; remarkably, this has caused my patients to take more ownership of their recovery,” he said.

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.